title: Abberant protein synthesis in G2019S LRRK2 Drosophila Parkinson disease-related phenotypes.
abstract: LRRK2 mutations are a frequent cause of familial Parkinson disease (PD) and are also found in a number of sporadic PD cases. PD-linked G2019S and I2020T mutations in the kinase domain of LRRK2 result in elevated kinase activity, which is required for the toxicity of these pathogenic variants in cell and animal models of PD. We recently reported that LRRK2 interacts with and phosphorylates a number of mammalian ribosomal proteins, several of which exhibit increased phosphorylation via both G2019S and I2020T LRRK2. Blocking the phosphorylation of ribosomal protein s15 through expression of phospho-deficient T136A s15 prevents age-associated locomotor deficits and dopamine neuron loss caused by G2019S LRRK2 expression in Drosophila indicating that s15 is a pathogenic LRRK2 substrate. We previously described that G2019S LRRK2 causes an induction of bulk mRNA translation that is blocked by T136A s15 or the protein synthesis inhibitor anisomycin. Here, we report the protective effects of the eIF4E/eIF4G interaction inhibitor 4EGI-1, in preventing neurodegenerative phenotypes in G2019S LRRK2 flies, and discuss how our findings and those of other groups provide a framework to begin investigating the mechanistic impact of LRRK2 on translation.
authors.affiliation: a Neuroregeneration and Stem Cell Programs; Institute for Cell Engineering; Johns Hopkins University School of Medicine ; Baltimore , MD USA.
authors.forename: Ian
authors.initials: I
authors.lastname: Martin
authors.forename: Leire
authors.initials: L
authors.lastname: Abalde-Atristain
authors.forename: Jungwoo Wren
authors.initials: JW
authors.lastname: Kim
authors.forename: Ted M
authors.initials: TM
authors.lastname: Dawson
authors.forename: Valina L
authors.initials: VL
authors.lastname: Dawson
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004330:Drosophila / Q000378:metabolism*; D029721:Drosophila Proteins / Q000378:metabolism*; D004353:Drug Evaluation, Preclinical; D006835:Hydrazones / Q000494:pharmacology / Q000627:therapeutic use*; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D010300:Parkinson Disease / Q000201:enzymology* / Q000235:genetics / Q000517:prevention & control; D010641:Phenotype; D014176:Protein Biosynthesis / Q000187:drug effects; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D012269:Ribosomal Proteins / Q000378:metabolism*; D013844:Thiazoles / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D029721:Drosophila Proteins; D006835:Hydrazones; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D017346:Protein Serine-Threonine Kinases; D012269:Ribosomal Proteins; D013844:Thiazoles; C517852:4EGI-1 compound; C036004:ribosomal protein S15; C543697:LRRK protein, Drosophila
keywords: 4EGI-1; LRRK2; Parkinson disease; anisomycin; s15